Difference between revisions of "Alpelisib (Piqray)"
Jump to navigation
Jump to search
m |
|||
| Line 10: | Line 10: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*5/24/2019: Approved in combination with fulvestrant for postmenopausal women, and men, with [[Biomarkers#HR|hormone receptor (HR)]]-[[Biomarkers#Expression|positive]], [[Biomarkers#HER2|human epidermal growth factor receptor 2 (HER2)]]-[[Biomarkers#Normal_expression|negative]], [[Biomarkers#PIK3CA|PIK3CA]]-[[Biomarkers#SNV|mutated]], [[Contexts#Advanced_or_metastatic|advanced or metastatic]] [[breast cancer]] as detected by an FDA-approved test [[Contexts#Subsequent-line_therapy|following progression]] on or after an [[Regimen_classes#Endocrine-based_regimen|endocrine-based regimen]]. ''(Based on [https://clinicaltrials.gov/ct2/show/NCT02437318 SOLAR-1])'' | *5/24/2019: Approved in combination with fulvestrant for postmenopausal women, and men, with [[Biomarkers#HR|hormone receptor (HR)]]-[[Biomarkers#Expression|positive]], [[Biomarkers#HER2|human epidermal growth factor receptor 2 (HER2)]]-[[Biomarkers#Normal_expression|negative]], [[Biomarkers#PIK3CA|PIK3CA]]-[[Biomarkers#SNV|mutated]], [[Contexts#Advanced_or_metastatic|advanced or metastatic]] [[breast cancer]] as detected by an FDA-approved test [[Contexts#Subsequent-line_therapy|following progression]] on or after an [[Regimen_classes#Endocrine-based_regimen|endocrine-based regimen]]. ''(Based on [https://clinicaltrials.gov/ct2/show/NCT02437318 SOLAR-1])'' | ||
| + | ==History of changes in EMA indication== | ||
| + | *7/27/2020: Initial authorization | ||
==Also known as== | ==Also known as== | ||
| Line 28: | Line 30: | ||
[[Category:FDA approved in 2019]] | [[Category:FDA approved in 2019]] | ||
| + | [[Category:EMA approved in 2020]] | ||
Revision as of 12:59, 31 December 2022
Mechanism of action
From NCI Drug Dictionary: An orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Alpelisib specifically inhibits PIK3 in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations.
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 5/24/2019: Approved in combination with fulvestrant for postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen. (Based on SOLAR-1)
History of changes in EMA indication
- 7/27/2020: Initial authorization
Also known as
- Code name: BYL719
- Brand name: Piqray